Encore Capital Group (ECPG) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

70OpportunityDD: Aug 25, 2026Analyst: 73

paidPrice at analysis date

USD 103.2 (25/08/2026)

domainMkt cap

$2.19B

pie_chartShares

21.21M

candlestick_chart52W

$39.95-$104.98

trending_downShort interest

5.64%

INFONASDAQInformation Technology7350 employeesFounded 1999

Verdict: Moderately Attractive — Value case largely priced in after +154% 1Y rally

Best-in-class debt buyer with record 2026 execution: Q2 EPS $2.81 (+13% YoY despite $1/sh refi cost), collections +13% to $737M, ROE 32%, guidance raised to $13-14 EPS. Fwd P/E ~7.5x is cheap in absolute terms but sits AT peer median; residual upside modest after the re-rating already delivered. High financial leverage (D/E 3.9x) and 2025 securities-class-action overhang cap the multiple.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-08-25

Encore Capital Group (ECPG)

Credit Services · NASDAQ · San Diego

"High-quality debt buyer at fair (not cheap) multiple after the 2026 re-rating."

ROE 32% EPS beat +12% Fwd P/E 7.5x Refi 2026 headwind D/E 3.9x

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — P/E-based (equity method, appropriate for levered specialty finance)

Fair value base case

USD 114.0

Range: USD 75.0-USD 145.0

Price at analysis date: USD 103.2 (25/08/2026)

Base upside/downside: +11%

P/E-based on FY2026E EPS midpoint $13.50 × 8.4x implied fwd P/E (peer median 8x + ROE premium − litigation haircut). Implied multiple sits within ±5% of nominal peer band (7-9x). EV/EBITDA cross-check delivers $82/sh, ~28% below P/E FV — divergence explained by $3.6B net debt compressing equity value under EV method. Sensitivity: ±1x P/E moves FV by ±$13.50/sh (~12%). ⚠️ Not investment advice.

Component	Assumption	USD/share
US debt purchasing (core earnings)	~72% of net income × $13.50 EPS × 8.0x peer-median fwd P/E	+77.76
Europe debt servicing/purchasing	~28% of net income × $13.50 EPS × 7.0x (lower growth, FX/regulatory)	+26.46
ROE premium adjustment	+0.5x P/E multiple × $13.50 (ROE 32% vs peer median ~15-20%)	+6.75
2026 refi cost reversal (FY27+)	+$1.00/sh normalized EPS × 6.0x (one-time headwind normalizes)	+6.00
Class action / litigation reserve	25% probability × ~$100M settlement / 21.21M shares = −$1.18/sh; discount value	−3.00
FV base case	Sum of components above (77.76 + 26.46 + 6.75 + 6.00 − 3.00)	≈ $114.00

Bull

$140–$145

Probability: 20%

FY26 EPS at high end $14, 2027 growth accelerates on US supply (+15% collections) as consumer credit deteriorates; multiple expands to 10x on best-in-class execution.

Base

$105–$125

Probability: 55%

EPS $13.5 (midpoint guidance), FY27 EPS $15-16 as refi headwind rolls off; multiple ~8-9x consistent with peer median. Modest re-rating room.

Bear

$70–$85

Probability: 25%

Credit cycle softens portfolio pricing; class action progresses to material settlement; multiple compresses to 6x on rising rate scare or covenant concerns; EPS $12.

Methodology: P/E-based on FY2026E EPS midpoint $13.50 × 8.4x implied fwd P/E (peer median 8x + ROE premium − litigation haircut). Implied multiple sits within ±5% of nominal peer band (7-9x). EV/EBITDA cross-check delivers $82/sh, ~28% below P/E FV — divergence explained by $3.6B net debt compressing equity value under EV method. Sensitivity: ±1x P/E moves FV by ±$13.50/sh (~12%). ⚠️ Not investment advice. Not investment advice.

⚠️ Methodology note: Market cap $2.19B sits just above the $300M–$2B "small cap" threshold — ECPG crossed the line via the +73% YTD rally after Q2 2026 earnings. Still analyzed as small-cap-borderline. Valuation uses P/E (equity-based) — most appropriate for a levered specialty-finance company where EBITDA is distorted by portfolio purchases (capex-like receivables acquisitions).

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

5.64%

1.21M shares shorted on 21.44M outstanding. Interpretation: moderate — some skepticism after the rally, no squeeze setup. Days to cover ~3.5.

🟢 Share dilution (1Y)

−1.1%

From ~21.44M to 21.21M via buybacks. Company repurchased ~$47M shares in H1 2026 alone, disciplined capital return.

🟢 Buyback

$47M H1'26

$27M in Q2 alone. Priority: opportunistic given fwd P/E <10x. Insider selling minimal (~$0.5M last 3 months, no buys).

Short Interest — context

ECPG — 5.64%

5.64%

Interpretation: 5.6% SI is moderate — the stock is not heavily shorted despite +154% 1Y rally, indicating the market broadly accepts the business improvement narrative. No squeeze catalyst. Insider transactions minimal ($0.5M sold in last 3 months, no buys) — neutral signal.

$Financial analysis — FY 2024–2026E

Revenue (TTM)

$1.85B

+28% YoY

Net Income (TTM)

$296M

Turnaround vs −$139M FY24

Diluted EPS (TTM)

$12.87

Guidance FY26: $13–$14

ROE (TTM)

31.96%

Best-in-class vs peers

Item	FY2023	FY2024	FY2025	Q2 2026 TTM	Guidance 2026
Total revenue ($M)	1,326	1,331	1,631	1,850	~1,900
Global collections ($M)	2,000	2,170	2,520	2,700	2,800–2,850
Portfolio purchases ($M)	1,076	1,350	1,410	1,450	1,400–1,500
Net income ($M)	92	−139	257	296	~285–300
Diluted EPS ($)	3.79	−5.83	10.91	12.87	13.00–14.00
Adj EBITDA ($M)	~500	~450	~700	~820	~850
ROE (%)	~8	n/m	~25	32	~30
Net debt ($M)	3,200	3,450	3,550	3,600	~3,550

FY24 net loss driven by $101M goodwill charge in Q4 (restructuring). FY25 recovery + FY26 acceleration confirms the operational turnaround; leverage stable in absolute terms while EBITDA scales.

Quarterly dynamics — last 5 quarters
Metric	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue ($M)	355	440	460	475	492
Collections ($M)	592	630	680	688	737
GAAP EPS ($)	1.72	3.17	2.15	4.05	2.81
EPS beat vs cons	+8%	+15%	+5%	+18%	+12%
End cash ($M)	170	195	215	220	227

Financial position and sustainability

Collections growth YoY

+13%

ROE (best-in-class)

32%

Debt/Equity (elevated)

3.9x

Fwd P/E vs peer median

7.5x vs 8.0x

account_tree

Business model — Debt purchasing & recovery specialist

Global debt recovery leader — capital-intensive, high-ROE compounder

Encore purchases portfolios of defaulted consumer receivables at deep discounts to face value (typically 5-10 cents on the dollar) via its US brand Midland Credit Management and European brand Cabot Credit Management, then collects over 7-10 years. Revenue = collections minus principal amortization. Business benefits from: (1) proprietary data on 45M+ accounts, (2) scale advantages in analytics/legal recovery, (3) countercyclical tailwind (delinquency rises → cheaper portfolio supply). Q2 2026 collections $737M is a company record; US supply particularly strong post-2024 credit normalization.

gavel

Legal, regulatory and risk analysis

Financial leverage (D/E 3.9x)

High

$3.85B total debt vs $970M equity. Debt is structural for the business model but leaves little buffer to rate shocks or portfolio-return misses. 2032 senior notes at 6.625% just refinanced $500M of 9.25% 2029 notes — good execution but expensive.

Securities class action overhang (2025)

Moderate

Multiple law firms (Rosen, Cruz, Glancy Prongay) opened investigations after Feb 2025 Q4 restructuring/$101M goodwill charge triggered a 21.9% single-day drop. Not yet a certified class; potential $50-150M exposure if settled. Watch lead-plaintiff deadlines.

CFPB / consumer regulation history

Moderate

2015 consent order + 2020 stipulated judgment resolved historical practice issues. Under a more consumer-friendly CFPB regime, debt buyers face perpetual scrutiny on collection practices. Not immediately material but structural.

Interest rate sensitivity (2026 refi drag)

Moderate

Q2 2026 EPS carried $1/sh drag from refinancing costs ($30.5M). $750M @ 6.625% + €325M floating notes issued 2026. Higher cost of capital compresses ROIC on new portfolio purchases; sensitivity: +50bps ≈ −$0.30/sh EPS.

Portfolio pricing / collections cycle

Moderate

US supply is currently favorable (rising defaults post-Covid stimulus wind-down); pricing discipline critical. If cycle softens or competitors overpay for portfolios, forward ROIC drops. Management flags US collections strength as thesis anchor.

Best-in-class ROE (32%)

Positive

Top of peer group vs PRAA ~15%, ATLC ~22%. Sustainable if collections growth continues; validates management execution and pricing discipline. Analyst research reports rate Value subrating "High".

Consistent EPS beats (5 consec quarters)

Positive

Q1 2026 +18%, Q2 +12%, Q3 2025 +15%, Q4 +5%, Q2 2025 +8%. Guidance raised twice in 2026. Track record supports execution premium in multiple.

Countercyclical tailwind + AI cost lever

Positive

Consumer credit deterioration = more supply, cheaper prices. AI/tech gains in collections efficiency (Zacks-flagged theme) could expand operating margins 100-200bps over 24 months.

article

SWOT analysis

Strengths

+Best-in-class ROE (32% vs peer median ~15-20%)
+Record Q2 2026 collections $737M (+13% YoY)
+5 consecutive quarterly EPS beats, guidance raised twice
+Global scale + proprietary data on 45M+ accounts
+Active buyback ($47M H1'26) at fwd P/E <10x

Weaknesses

−D/E 3.9x — highest among peers
−FY24 net loss ($139M) still recent — recovery narrative
−Refi headwind: $1/sh EPS drag in Q2 2026 alone
−Argus rates Safety + Financial Strength "Low"
−Class action investigation open (2025 disclosures)

Opportunities

→US portfolio supply strong post-credit normalization
→AI-driven collections efficiency gains (+100-200bps margin)
→Fed rate cuts would reduce refi cost of capital
→European deleveraging cycle continues in H2 2026
→Multiple expansion to 9-10x if track record consolidates

Threats

!Consumer credit cycle inflection (portfolio pricing risk)
!Class action material settlement ($50-150M possible)
!CFPB/consumer regulation shift (structural risk)
!Peer competition bidding up US portfolio prices
!Post-rally profit-taking: stock +154% 1Y, near 52W high

article

Summary by assessment area

🟢 Business risk — Low

Global leader in a countercyclical niche
Record execution 2026: collections +13%, EPS beats consistently
ROE 32% best-in-class

🟡 Financial risk — Moderate

D/E 3.9x — high but structural for debt buyers
Refi costs $30.5M in Q2 26 ($1/sh drag)
Cash $227M, adequate liquidity but tight

🟡 Valuation risk — Moderate

Fwd P/E 7.5x — cheap absolute, AT peer median
+154% 1Y rally has closed the historical discount
Base upside +10.5%; residual value case moderate

{ "verdict_label": {"it": "Giudizio: Moderatamente Attraente", "en": "Verdict: Moderately Attractive"}, "verdict_text": {"it": "Debt buyer di qualita' con esecuzione record 2026 (ROE 32%, 5 EPS beats consecutivi), ma dopo +154% 1Y la valutazione a P/E fwd 7.5x sta gia' AL livello dei peer. Residuo upside limitato (~+10%). Alta leva (D/E 3.9x) e class action del 2025 limitano l'espansione del multiplo.", "en": "Best-in-class debt buyer with record 2026 execution (ROE 32%, 5 consecutive EPS beats), but after +154% 1Y rally the fwd P/E 7.5x sits AT peer median. Residual upside modest (~+10%). High leverage (D/E 3.9x) and 2025 securities class action cap multiple re-rating."}, "bull_points": [ {"it": "ROE 32% best-in-class + collections Q2 +13% a $737M record", "en": "ROE 32% best-in-class + Q2 collections +13% to record $737M"}, {"it": "5 EPS beat consecutivi, guidance FY26 alzata a $13-14 EPS", "en": "5 consecutive EPS beats, FY26 guidance raised to $13-14 EPS"}, {"it": "Fed cuts + rollover refi riducono cost of capital in FY27+", "en": "Fed cuts + refi rollover reduce cost of capital FY27+"} ], "bear_points": [ {"it": "Fwd P/E 7.5x gia' al livello dei peer dopo il rally +154% 1Y", "en": "Fwd P/E 7.5x already at peer median after +154% 1Y rally"}, {"it": "D/E 3.9x altissimo, Argus rating Safety+Fin Strength Low", "en": "D/E 3.9x elevated, Argus Safety+Fin Strength subratings Low"}, {"it": "Refi Q2 2026 ha eroso $1/sh EPS, headwind residuo in 2027", "en": "Q2 2026 refi eroded $1/sh EPS, residual headwind into 2027"} ], "risks": [ {"it": "Class action securities 2025 non ancora certificata: potenziale settlement $50-150M", "en": "2025 securities class action not yet certified: potential $50-150M settlement exposure"}, {"it": "Inflessione del ciclo del credito consumer USA comprime pricing dei portafogli", "en": "US consumer credit cycle inflection compresses portfolio pricing"}, {"it": "Post-rally profit taking: prezzo vicino a 52W high $104.98", "en": "Post-rally profit taking: price near 52W high $104.98"} ] }

Sources & Disclaimer

Sources: TradingKey (close Aug 24, 2026 $103.16), Yahoo Finance / Nasdaq, SEC 8-K filings FY2026, GuruFocus, Zacks, Simply Wall St, Encore Capital IR (Q2 2026 press release Aug 5, 2026), Motley Fool earnings transcripts, Rosen Law / Cruz / Glancy Prongay investigation press releases, Argus Research (Aug 2026 Buy target $101), Citizens JMP (Jun 17, 2026 Market Outperform target $115). Market data — last verified close 2026-08-24: ECPG ~$103.16, market cap ~$2.19B, 52W: $39.95–$104.98, 21.21M shares outstanding. Short interest: 5.64% (1.21M shares). ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.